SCHEMBL6154448

SCHEMBL6154448

NC(=O)c1ccc(NC(=O)C2CCCN(Cc3ccccc3)C2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.61
ROCK1 Q13464 2/20 0.61
CCR2 P41597 1/20 0.61
DRD3 P35462 1/20 0.56
GAA P10253 1/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP1A2 P05177 1/20 0.55
KDM4E B2RXH2 2/20 0.54
KMT2A Q03164 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
SCN4A P35499 2/20 0.54
BCHE P06276 2/20 0.54
MAOB P27338 2/20 0.54
CYP2D6 P10635 1/20 0.53
ACHE P22303 1/20 0.52
LTA4H P09960 1/20 0.52
CACNA1G O43497 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154047 0.86 LTA4H (0.67) ROCK2ROCK1GAALTA4H
SCHEMBL1553646 0.84 CYP3A4 (0.69) ROCK2ROCK1CCR2DRD3CYP3A4
SCHEMBL6153437 0.82 ROCK2 (0.60) ROCK2ROCK1CCR2GAAALDH1A1
SCHEMBL4792481 0.81 KDM4E (0.63) ROCK2ROCK1CCR2GAACYP3A4
SCHEMBL4792478 0.81 KDM4E (0.63) ROCK2ROCK1CCR2GAACYP3A4
SCHEMBL2444402 0.79 GAA (0.77) GAACYP3A4CYP2C9CYP1A2KDM4E
SCHEMBL3314498 0.79 GAA (0.77) GAACYP3A4CYP2C9CYP1A2KDM4E
SCHEMBL5870879 0.78 DRD3 (0.77) ROCK2ROCK1CCR2DRD3GAA
SCHEMBL6154433 0.77 LTA4H (0.61) ROCK2ROCK1CCR2DRD3GAA
SCHEMBL6156841 0.77 GAA (0.59) ROCK2ROCK1CCR2GAABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 ROCK2 2/4885ROCK1 1/4885CCR2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.